Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Aura Biosciences Inc (AURA – Research Report). The associated price target is $22.00.
Edward White’s rating is based on the promising development and future potential of Aura Biosciences’ lead product candidate, bel-sar. The drug has shown encouraging results in early trials for non-muscle invasive bladder cancer (NMIBC), with a significant number of patients demonstrating positive clinical responses. Additionally, bel-sar has received FDA Fast Track Designation, highlighting its potential impact in treating NMIBC, which represents a large portion of new bladder cancer cases.
Furthermore, bel-sar is advancing in ocular oncology, specifically for early-stage choroidal melanoma, where it has also received Orphan Drug Designation. The ongoing Phase 3 CoMpass trial aims to establish its efficacy and safety, with a commercial launch anticipated in 2027. The potential market for bel-sar in both bladder and ocular cancers, along with projected sales growth, supports the Buy rating. Edward White’s analysis incorporates a thorough evaluation of the drug’s prospects, market potential, and financial forecasts, leading to a price target of $22.
In another report released on February 20, JMP Securities also reiterated a Buy rating on the stock with a $21.00 price target.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AURA in relation to earlier this year.